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Mutations in AGBL1 Cause
Dominant Late-Onset Fuchs Corneal Dystrophy
and Alter Protein-Protein Interaction with TCF4
S. Amer Riazuddin,1 Shivakumar Vasanth,2 Nicholas Katsanis,2 and John D. Gottsch1,*
Fuchs corneal dystrophy (FCD) is a hereditary dystrophy of the corneal endothelium and is responsible for majority of the corneal
transplantation performed in the United States. Here, we describe three generations of a family with 12 individuals affected by late-onset
FCD and in which three individuals are unaffected. Genome-wide mapping provided suggestive linkage at two loci on chromosomal
arms 3p and 15q. Alleles at either locus alone were not sufficient to explain FCD; however, considered together, both loci could explain
the disorder in this pedigree. Subsequent next-generation sequencing identified a nonsense mutation in AGBL1 in the 15q locus; this
mutation would result in a premature termination of AGBL1. Consistent with a causal role for this transcript, further sequencing of
our cohort of late-onset-FCD-affected individuals identified two cases harboring the same nonsense mutation and a further three
unrelated individuals bearing a secondmissense allele. AGBL1 encodes a glutamate decarboxylase previously identified in serial analysis
of gene expression of corneal endothelium, a finding confirmed by immunohistochemical staining. Wild-type AGBL1 localizes predom-
inantly to the cytoplasm; in sharp contrast, the truncated protein showed distinct nuclear localization. Finally, we show that AGBL1
interacts biochemically with the FCD-associated protein TCF4 and that the mutations found in our cohort of FCD individuals diminish
this interaction. Taken together, our data identify a locus for FCD, extend the complex genetic architecture of the disorder, provide direct
evidence for the involvement of TCF4 in FCD pathogenesis, and begin to explain how causal FCDmutations affect discrete biochemical
complexes.Fuchs corneal dystrophy (FCD) is the most common
genetic disorder of the corneal endothelium1–3 and
accounts for a significant fraction of the corneal transplan-
tations performed in the United States yearly.4,5 Clinically,
FCD is marked by thickening of Descemets membrane and
excrescences, called guttae, that appear typically in the
fourth or fifth decade.6,7 Disease progression results in
decreased visual acuity as a result of increasing corneal
edema, and end-stage disease is marked by painful epithe-
lial bullae.8
FCD is genetically heterogeneous. A rare early-onset
form of an endothelial dystrophy with some of the clinical
features of FCD has been ascribed to mutations in COL8A2
(MIM 120252),9,10 whereas mutations in SLC4A11
(MIM 610206), TCF8 (MIM 189909), and LOXHD1 (MIM
613267) have been implicated in the pathogenesis of
the common form of late-onset FCD.9–15 Additionally,
researchers have used large pedigrees that exhibit
dominant inheritance with nonpenetrance and variable
expressivity to map four loci, FCD1, FCD2, FCD3, and
FCD4, on chromosomes 13, 18, 5, and 9, respec-
tively.13,16–18 Finally, rs613872, a common intronic SNP
at the TCF4 (MIM 602272) locus on chromosomal arm
18q has also been associated with late-onset FCD.19–21
However haplotype analyses have suggested that this
risk factor is most likely independent of FCD2,21 inti-
mating that multiple loci might account for the repli-
cated linkage and association signals on chromosomal
arm 18q.1The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Balti
sity, Durham, NC 27709, USA
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758 The American Journal of Human Genetics 93, 758–764, OctoberAs part of our ongoing effort to understand the genetic
and molecular pathomechanisms of FCD, we recruited a
large, three-generation family, DA (Figure 1). All partici-
pating individuals provided an informed written consent
prior to joining the study, which was approved by the
Johns Hopkins University School of Medicine Institutional
Review Board (IRB) and was performed in accordance with
the tenets of the Declaration of Helsinki. Overall, we were
able to recruit and examine through slit-lamp bio-
microscopy 16 individuals. Of these, we found 12 (nine fe-
males, three males) who fulfilled the phenotypic criteria
for an FCD diagnosis (12 or more central guttae in one or
in both eyes of individuals above 60 years of age). The clin-
ical characteristics of the affected individuals of family DA
present a nonuniform severity profile that typifies this dis-
order; some of those affected manifested a severe clinical
phenotype, whereas others presented a milder phenotype
(Table 1).
We first asked whether FCD in this family might be
linked to any of the four reported FCD loci and/or whether
affected family members might harbor mutations in
the three genes causally associated with late-onset FCD.
Therefore, we genotyped all available individuals with
STR (short tandem repeat) microsatellite markers that
span the critical intervals of FCD1–FCD4; both haplotype
and linkage analyses ruled out these four loci (data
not shown). Next, we sequenced all the coding exons
along with the exon-intron boundaries of SLC4A11,
TCF8, and LOXHD1; we did not find any causal variantsmore, MD 21287, USA; 2Center for Human Disease Modeling, Duke Univer-
y of Human Genetics. All rights reserved.
3, 2013
Figure 1. Family DA Cyrillic Pedigrees Showing Haplotype, Alleles of Chromosomal Arm 3p and 15q STR Markers, and the Presence
of the c.3082C>T Variant Identified in AGBL1
(A) Alleles forming haplotypes at chromosomal arm 3p.
(B) Alleles forming haplotypes at chromosomal arm 15q.
Filled symbol: affected individual. Diagonal line through a symbol: deceased individual. Black bars: alleles forming the disease-bearing
haplotype. Note: A dot represents an individual who possesses less than 12 central guttae in one or both eyes and who therefore cannot
be graded ‘‘1’’ on the Krachmer scale.(data not shown). Taken together, these data are suggestive
of a hitherto unknown gene or locus as the driver for FCD
in this family.
To map such a locus, we performed a genome-wide two-
point linkage analysis under an autosomal-dominant
model with a disease allele frequency of 0.04. Initial ana-
lyses failed to detect any loci with significant LOD scores.
We therefore took into consideration the nonuniform
severity profile of family DA and reasoned that FCD in
this family might be heterogeneous and that multiple
causal alleles might be responsible for the disease pheno-
type, a phenomenon we have observed previously in our
linkage and positional cloning studies of this disorder.13
Thus, we recomputed linkage under a multi-locus model
under the following conditions: (1) all individuals with
FCD at a severity of >3.0 bilaterally on the Krachmer scaleThe Americmust harbor alleles at each locus; (2) individuals with FCD
at a Krachmer grade % 3.0 might harbor alleles at each
locus; and (3) individuals whose parents both exhibit
symptoms of FCD might not harbor alleles at any loci
(the assumption was that these individuals manifest FCD
as a result of a causal allele received from the parent
marrying into the family DA). Even under these condi-
tions, we did not find significant linkage; however, we
did note two loci on chromosomal arms 3p and 15q; these
were the only appreciable positive signals in the genome-
wide scan.
To explore this finding further, we performed next-gen-
eration sequencing to pair-end sequence the exome of
two affected individuals and one unaffected individual of
family DA at the Cincinnati Children’s Hospital and Med-
ical Center (CCHMC) core facility. Genomic DNAs werean Journal of Human Genetics 93, 758–764, October 3, 2013 759
Table 1. Clinical Characteristics of the Affected Individuals of
Family DA
ID Age (Years) Sex
Severity
AGBL1 MutationOD OS
I:1 89 F PK PK c.3082C>T
II:1 71 M 3.5 1.5 wild-type
II:2 70 F 1.0 1.0 wild-type
II:3 69 F 2.0 2.0 c.3082C>T
II:4 65 M Trace - wild-type
II:6 69 F 5 5 c.3082C>T
II:8 64 F 1.5 1.5 c.3082C>T
II:10 59 M 2.5 3.0 c.3082C>T
II:11 57 F 1.5 2.0 c.3082C>T
II:12 55 F 3.5 3.5 c.3082C>T
III:1 47 F Trace 1.0 wild-type
III:2 35 F 2.5 2.0 c.3082C>T
III:4 39 M 1.0 1.25 wild-type
OD: oculus dexter (right eye). OS: oculus sinister (left eye). PK: penetrating ker-
atoplasty. F: female. M: male. Penetrating keratoplasty was performed on each
eye separately, and only once had the severity of disease reached 6 on the
modified scale proposed by Krachmer and colleagues.6 Note: Individual II:6
has undergone penetrating keratoplasty since the first examination.captured with the Agilent SureSelect Human All Exon kit
according to the manufacturer’s instructions (Agilent).
Subsequent to capture and enrichment, the paired-end
library was sequenced on the Illumina HiSeq2000 Genome
Analyzer (Illumina). Multiplexing of three samples per
lane on a HiSeq 2000 Genome Analyzer generated >108
paired-end reads per lane. We determined that 75% of
reads for each sample aligned to the reference sequence
and passed quality-control filters, which was sufficient
to generate on average 503 coverage for the exome,
including both potential critical intervals.
The raw data were aligned to the UCSC Hg19 reference
sequence by ELAND and mapped to the UCSC Hg19
reference sequence by SeqMate; SNP and INDEL (inser-
tion/deletion) calls for each sample were made according
to the GATK recommendations. The whole-exome data
consisted on average of ~30,000 single-base changes
and ~1,500 insertion/ deletions (indels). We examined
these data by passing them through our filtering pipe-
line. First, we removed all the variants that were not pre-
sent in either linkage interval. Subsequently, we removed
all the alleles that were homozygous for the reference
allele in the affected individuals. Next, we removed all
variants that were heterozygous or homozygous for
the alternative (nonreference) allele in the unaffected
individual. Finally, we excluded all SNPs with a minor-
allele frequency (MAF) > 2% in one or both affected
individuals. We termed the resulting set of alleles as
potential casual variants and confirmed them by dideoxy
sequencing.760 The American Journal of Human Genetics 93, 758–764, OctoberWe identified four potential causal variants residing in
the chromosome 3 region; however, none of them passed
the criterion of FCD causality, suggesting (1) that this locus
is an artifact and/or false-positive signal due to a miscall of
alleles, (2) that the causal driver in that region does not
fulfill our genetic filtering criteria, or (3) that the allele
on chromosome 3 was not covered by the exome capture.
In contrast, we found a C-to-T transition, c.3082C>T
(Figure S1A) in ATP/GTP binding protein-like 1 (AGBL1;
RefSeq accession number NM_152336.2), a metallocar-
boxypeptidase that mediates deglutamylation of target
proteins residing with the putative critical interval on
chromosome 15. The variant results in a premature stop
codon at position 1028: p.Arg1028*. Subsequent dideoxy
sequencing in the entire sibship showed that this allele
segregated with an FCD haplotype in family DA (Figure 1)
under the multi-locus model. Subsequently, we evaluated
384 ethnically matched controls (768 chromosomes) that
had been examined thoroughly to exclude anterior
segment anomalies and searched the NHLBI exome variant
server database for the presence of the c.3082C>T variant.
We did find this variant in two control subjects and in the
NHLBI exome variant server database; however, the MAFs
of 0.0026 and 0.0035 observed in control subjects and in
the Northern European (Caucasian American) population,
respectively, is considerably below the >4% prevalence of
late-onset FCD in the US population.
To evaluate the candidacy of AGBL1 further, we
sequenced our entire FCD cohort of simplex and familial
cases irrespective of known mutational burden. We identi-
fied two unrelated FCD-affected individuals who harbor
the same nonsense mutation as the one found in family
DA. In addition, we found a heterozygous missense
variant, c.2969G>C (Figure S1B) that results in noncon-
served amino acid substitution (p.Cys990Ser). The Cys at
position 990 is completely conserved in all recognizable
AGBL1 orthologs of the 32 species reported in the UCSC
genome browser (Figure S2). This allele was absent from
384 ethnically matched controls but present in NHLBI
exome variant server at a low MAF of 0.0025 in the Euro-
pean American population.
We noted that AGBL1 was identified previously in serial
analysis of gene expression (SAGE) of human corneal
endothelium (HCE).22 To provide biological verification
of that observation, we extracted HCE from postmortem
eyes. We purified total RNA with Trizol (Invitrogen), and
we synthesized cDNA (Invitrogen) with polydT specific
primers. We then used custom Taqman probes to perform
quantitative RT-PCR in triplicatewith an Applied Bio-
systems 7900HT system. Results were analyzed with
sequence-detection software (Applied Biosystems). We
recorded the mean threshold cycle (CT) value for each
target (AGBL1) and endogenous reference (b-actin); this
value represents the PCR cycle at which the ABI 7900HT
detection system first detects a noticeable increase in
reporter florescence above the baseline signal. We were
able to detect expression of AGBL1 in HCE at low levels3, 2013
Figure 2. Immunohistochemical Analyses of AGBL1 in 10 mm Cryosections of Human Cornea from a Patient Who Had Undergone
Corneal Transplantation
For examination of AGBL1 expression in corneal endothelium, cornea sections were stained with (A) DAPI and (B) AGBL1 antibody,
whereas control slides were stained only with (E) DAPI and (F) the secondary antibody. (C and G) Merged view of images shown in
(A) and (B) and in (D) and (E), respectively. (D and H) Enlarged images of boxed areas in (C) and (G).(data not shown), confirming the expression of AGBL1 in
corneal endothelial cells.
In parallel, we evaluated the presence of AGBL1 in a
human corneal section of a patient who had undergone
corneal transplantation. Corneal tissue was fixed with
formaldehyde and embedded in paraffin; 12-mm-thick sec-
tions were treated with rabbit polyclonal anti-ABGL1 anti-
body (Sigma-Aldrich) at 1:250 dilution for 4 hr at room
temperature or overnight at 4C, then with anti-rabbit
IgG conjugated with AlexaFluor 594 at a 1:400 dilution
(Jackson Immuno Research). Slides were costained for
nuclei with DAPI (40, 6-diamidino-2-phenylindole) at a
1:10,000 dilution(Sigma-Aldrich). Control slides were
only stained with anti-rabbit IgG conjugated with Alexa-
Fluor 594 and DAPI. Sectioned images were captured
with a Zeiss-Axioskop2microscope (Carl Zeiss Microscopy)
and digitalized with ImagePro plus software, which
showed distinct staining in the corneal endothelium
(Figure 2).
Next, to examine the localization pattern of wild-type
and mutant AGBL1, we obtained a commercially available
AGBL1 cDNA (GeneCopoeia, Rockville MD) and cloned
into a 3X-Flag-tagged vector (3XFlag-pCMV10, Sigma) by
amplifying the wild-type cDNA and ligating with vector
by In-Fusion cloning (Clontech) as per the manufacturer’s
protocol. Both the missense and nonsense mutations were
constructed with the QuikChange II XL Site-Directed
Mutagenesis Kit (Agilent). NIH 3T3 cells were grown on
cover glass pretreated with poly-L-lysine and were trans-
fected with 1.5 mg of wild-type and mutant AGBL1 Flag-
tagged constructs and Lipofectamine 2000 (Invitrogen).
Cells were fixed 24 hr after transfection in 4% PFA, permea-The Americbilized, and blocked in 0.1% Triton X-100 and 1% BSA in
PBS. Cells were incubated with primary and secondary
antibodies at room temperature for 1 hr in blocking buffer,
treated with DAPI, and mounted with VectaShield (Vector
Laboratories) mountingmedium. As shown in Figure 3 and
Figure S3, the wild-type and the missense mutant localized
to the cytoplasm. In sharp contrast, the mutant protein
lacking 38 amino acids from the C terminus localized pre-
dominantly to the nucleus (p ¼ 0.0001).
Taken together, our data indicate that mutations in
AGBL1 are causal to late-onset FCD and account for
approximately 1%–2% of the genetic burden of the disor-
der. This contribution is similar to that of LOXHD1,
SLC4A11, and TCF8 mutations. To interrogate the biolog-
ical significance of these findings, we asked whether
AGBL1 might participate in the same biological processes
as other genes previously implicated in the pathogenesis
of FCD, including the associated locus TFC4. LOXHD1
and SLC4A11 are both plasma membrane proteins; how-
ever, being a transcription factor, TCF8 is found primarily
in the nucleus. We therefore decided to examine the possi-
bility that AGBL1 can interact biochemically with TCF8
(especially because one of the AGBL1 mutants is found
abundantly in the nucleus). We also included TCF4,
another transcription factor, because rs613872 has been
associated with late-onset FCD.
HEK293 cells were transfected with Flag-AGBL1 and
tested for its interaction with either Myc-TCF4 or Myc-
TCF8. Two days after transfection, cells were lysed in a
Triton lysis buffer with protease inhibitor cocktail and
centrifuged at 13,000 g for 30 s. Lysates were then immu-
noprecipitated with anti-Flag-M2-antibody-conjugatedan Journal of Human Genetics 93, 758–764, October 3, 2013 761
Figure 3. The AGBL1 Nonsense Variant Is Enriched in the
Nucleus
NIH 3T3 cells were transfected with plasmids encoding Flag-
tagged wild-type AGBL1 and with the two mutants, p.Cys990Ser
and p.Arg1028*. Cells were stained with anti-Flag antibody (A,
D, G) and DAPI (B, E and H) and co-localization was visualized
by merging the two images (C, F, and I).
Figure 4. AGBL1 Interacts with a Previously Identified Fuchs
Locus, TCF4
(A) HEK293 cells were transfected with Flag-AGBL1 and tested for
its interaction with either Myc-TCF4 or Myc-TCF8, as shown.
Immunoprecipitated lysates suggested that AGBL1 specifically in-
teracts with TCF4 and not with TCF8.
(B) HEK293 cells were cotransfected with TCF4 and AGBL1 wild-
type construct and two variants. The two AGBL1 mutants,
p.Cys990Ser and pArg1028*, interact with TCF4; however, the
amount of immunoprecipitated protein is diminished signifi-
cantly in comparison to wild-type AGBL1, despite the higher pro-
tein amounts of mutant AGBL1.
Note: The asterisk in panels (A) and (B) indicates the heavy chain
of IgG antibody that was used for immunoprecipitation.agarose beads (Sigma), or normal mouse IgG (Santa Cruz)
bound to Protein-G agarose (Santa Cruz) overnight at
4C. Lysates were thenwashed three times with Triton lysis
buffer. Immunoprecipitated lysates probed with anti-Myc
antibody suggested that AGBL1 interacts specifically with
TCF4, but not with TCF8 (Figure 4A).
The nonsense mutation in our three FCD cases is pre-
dicted to abolish the terminal 38 amino acids, whereas
the missense allele was found to be a conserved residue
in the other three independent FCD cases. Given the
observed interaction with TCF4, we wondered whether
these two variations in AGBL1 might perturb that interac-
tion. Transfection with each of the two mutant forms of
AGBL1 and wild-type TCF4 showed that the introduction
of the C-terminal deletion (p.Arg1028*) significantly in-
creases the abundance of AGBL1, whereas the p.Cys990Ser
variation diminished the relative abundance of AGBL1 in
comparison to the wild-type AGBL1 (Figure 4B). The differ-
ence in the relative protein levels of mutant AGBL1
strongly predicts altered stability of the mutant proteins
compared to the wild-type AGBL1. Furthermore, immuno-
precipitation of either of the two mutant alleles sig-
nificantly reduced binding affinity to TCF4 (Figure 4B),
suggesting that ablation of this interaction might
contribute to disease pathogenesis.
Here we have identified AGBL1 as a causal locus for late-
onset FCD. Similar to other genes previously implicated in
the pathogenesis of FCD, most notably TCF8,13 the famil-
ial inheritance pattern of AGBL1 is not purely Mendelian,762 The American Journal of Human Genetics 93, 758–764, Octoberas evidenced by the fact that three FCD in affected individ-
uals in our index pedigree had been contributed by
another locus (there was a possible signal on chromo-
some 3). This is not surprising, given the high frequency
of the disease in the adult population and the recent
documentation of both common and rare alleles, identi-
fied though a blend of association and targeted resequenc-
ing studies and affecting the causality and modification
of the phenotypic expressivity of the disorder in
FCD-affected individuals.13 Despite these complexities,
however, the study of large multigenerational pedigrees3, 2013
remains important in the discovery of causal alleles in
FCD.13–15,18 Here, we add a glutamylase to the series of
proteins that drive the disorder. The glutamylase enzyme
(metallocarboxypeptidase) catalyzes the deglutamylation
of polyglutamate side chains generated by posttransla-
tional polyglutamylation in proteins.23 It has been shown
that controlling the length of the polyglutamate side
chains on tubulin is critical for neuronal survival and
that the lack of such control results in neurodegeneration
in mice.23
Importantly, the observed interaction between AGBL1
and TCF4 directly intimates the latter protein in the causal-
ity of FCD (prior evidence being exclusively based on
GWAS association) and provides a potential mechanism
for the observed AGBL1 mutations. We speculate that
TCF4 might be an enzymatic target for AGBL1. Although
this result will require experimental validation, it is
tempting to speculate that other targets of AGBL1 might
now become natural candidates for causing FCD as well,
whereas restoration of lost glutamylase activity and its
consequences might be an area of potential therapeutic-
target development.Supplemental Data
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